```
File   5:Biosis Previews(R) 1969-2004/May W5
         (c) 2004 BIOSIS
  File  73:EMBASE 1974-2004/May W5
         (c) 2004 Elsevier Science B.V.
  File 155:MEDLINE(R) 1966-2004/May W5
         (c) format only 2004 The Dialog Corp.
*File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.
  File 399:CA SEARCH(R) 1967-2004/UD=14024
         (c) 2004 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? e au=lin rong-hwa ?

Ref   Items  Index-term
E1        3  AU=LIN RONG-HUA
E2       30  AU=LIN RONG-HWA
E3        0 *AU=LIN RONG-HWA ?
E4        1  AU=LIN RONG-JING
E5        8  AU=LIN RONG-JYH
E6        1  AU=LIN RONG-LUH
E7        1  AU=LIN RONG-SHINN
E8        2  AU=LIN RONG-XI
E9        2  AU=LIN RONGBIAO
E10       1  AU=LIN RONGCHEN
E11       2  AU=LIN RONGFU
E12       1  AU=LIN RONGGEN

          Enter P or PAGE for more
? s e1-e3
              3  AU=LIN RONG-HUA
             30  AU=LIN RONG-HWA
              0  AU=LIN RONG-HWA ?
      S1     33  E1-E3
? e au=wu chung-hsiun ?

Ref   Items  Index-term
E1        6  AU=WU CHUNG-HSING
E2        2  AU=WU CHUNG-HSIUN
E3        0 *AU=WU CHUNG-HSIUN ?
E4        2  AU=WU CHUNG-HSIUN H
E5        3  AU=WU CHUNG-HSIUN HERBERT
E6        1  AU=WU CHUNG-HSIUN HEREBERT
E7        5  AU=WU CHUNG-HSUN
E8       62  AU=WU CHUNG-I
E9        5  AU=WU CHUNG-JUNG
E10       1  AU=WU CHUNG-LIN
E11      12  AU=WU CHUNG-MAY
E12       1  AU=WU CHUNG-MING

          Enter P or PAGE for more
? s e2-e7
              2  AU=WU CHUNG-HSIUN
              0  AU=WU CHUNG-HSIUN ?
              2  AU=WU CHUNG-HSIUN H
              3  AU=WU CHUNG-HSIUN HERBERT
              1  AU=WU CHUNG-HSIUN HEREBERT
              5  AU=WU CHUNG-HSUN
      S2     13  E2-E7
? e au=hsu pei-ling ?
```

```
Ref    Items  Index-term
E1         0 *AU=HSU PEI-LING ?
E2         1  AU=HSU PEI-SHUANG
E3         2  AU=HSU PEI-YU
E4         6  AU=HSU PEI-YUNG
E5         1  AU=HSU PEIHONG
E6         1  AU=HSU PENG-LIN
E7         2  AU=HSU PENG-WEI
E8         1  AU=HSU PETER C
E9         1  AU=HSU PHILIP
E10        2  AU=HSU PHILLIP
E11        1  AU=HSU PI-CHANG
E12        5  AU=HSU PI-CHEN

          Enter P or PAGE for more
? s s(1 or s2) and (psgl?)
                0  S(1
               13  S2)
             1291  PSGL?
      S3        0  S(1 OR S2) AND (PSGL?)
? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand) and (diabetes
>>>Unmatched parentheses
? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand) and (diabetes)
             1291  PSGL?
          4542066  P
            33878  SELECTIN
           291626  GLYCOPROTEIN
           384590  LIGAND
             1323  P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND
           589096  DIABETES
      S4       15  (PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND
                   (DIABETES)
? rd s4
...completed examining records
      S5       10  RD S4 (unique items)
? t s5/7/all

 5/7/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014384123   BIOSIS NO.: 200300340866
Protein kinase C beta2-dependent phosphorylation of core 2 GlcNAc-T
  promotes leukocyte-endothelial cell adhesion: A mechanism underlying
  capillary occlusion in diabetic retinopathy.
AUTHOR: Chibber Rakesh (Reprint); Ben-Mahmud Bahaedin M; Mann Giovanni E;
  Zhang Jin J; Kohner Eva M
AUTHOR ADDRESS: Centre for Cardiovascular Biology and Medicine, GKT School
  of Biomedical Sciences, King's College London, 2nd Floor, New Hunt's
  House, London, SE1 1UL, UK**UK
AUTHOR E-MAIL ADDRESS: rakesh.chibber@kcl.ac.uk
JOURNAL: Diabetes  52 (6): p1519-1527 June 2003 2003
MEDIUM: print
ISSN: 0012-1797 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Increased leukocyte-endothelial cell adhesion is a key early
  event in the development of retinopathy and atherogenesis in diabetic
  patients. We recently reported that raised activity of glycosylating
  enzyme (beta)11,6 acetylglucosaminyltransferase (core 2 GlcNAc-T) is
  responsible for increased leukocyte-endothelial cell adhesion and
  capillary occlusion in retinopathy. Here, we demonstrate that elevated
```

glucose increases the activity of core 2 GlcNAc-T and adhesion of human leukocytes to retinal capillary endothelial cells, in a dose-dependent manner, through **diabetes**-activated serine/threonine protein kinase C beta2 (PKCbeta2)-dependent phosphorylation. This regulatory mechanism, involving phosphorylation of core 2 GlcNAc-T, is also present in polymorphonuclear leukocytes isolated from type 1 and type 2 diabetic patients. Inhibition of PKCbeta2 activation with the specific inhibitor, LY379196, attenuated serine phosphorylation of core 2 GlcNAc-T and prevented increased leukocyte-endothelial cell adhesion. Raised activity of core 2 GlcNAc-T was associated with a threefold increase in O-linked glycosylation of **P-selectin glycoprotein ligand**-1 on the surface of leukocytes of diabetic patients compared with age-matched control subjects. PKCbeta2-dependent phosphorylation of core 2 GlcNAc-T may thus represent a novel regulatory mechanism for activation of this key enzyme in mediating increased leukocyte-endothelial cell adhesion and capillary occlusion in diabetic retinopathy.

5/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013998538 BIOSIS NO.: 200200592049
Administration of recombinant **P-selectin glycoprotein ligand** Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model
AUTHOR: Zhou Zhongmin; Penn Marc S; Forudi Farhad; Zhou Xiaorong; Tarakji Khaldoun; Topol Eric J; Lincoff A Michael; Wang Kai (Reprint)
AUTHOR ADDRESS: Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave, F25, Cleveland, OH, 44195, USA**USA
JOURNAL: Arteriosclerosis Thrombosis and Vascular Biology 22 (10): p 1598-1603 October, 2002 2002
MEDIUM: print
ISSN: 1079-5642
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Objective: P-selectin-mediated leukocyte-endothelium and leukocyte-platelet interaction has been reported after vascular injury and has been correlated with neointimal hyperplasia, but its role in neointimal formation after arterial injury in **diabetes** has not been described. Methods and Results: Using a Zucker diabetic rat balloon injury model, we examined the role of P-selectin in the vascular inflammatory process and neointimal formation after balloon injury. Immunohistochemistry revealed that P-selectin was intensely expressed and that CD45-positive leukocyte infiltration was significantly increased after arterial injury. A single preprocedural intravenous administration of a recombinant P-selectin-soluble glycoprotein ligand-Ig inhibited CD45-positive leukocyte accumulation and suppressed neointimal formation in the Zucker diabetic rat model. Conclusions: These results suggest that reduction of P-selectin-mediated leukocyte activation with the use of recombinant P-selectin-soluble glycoprotein ligand-Ig decreases the inflammatory response and limits neointimal formation after balloon injury in ***diabetes*** .

5/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013814769 BIOSIS NO.: 200200408280
P-selectin neutralization prevents neointimal formation in a diabetic rat model

AUTHOR: Zhou Zhongmin (Reprint); Wang Kai (Reprint); Forudi Farhad (Reprint); Zhou Xiaorong (Reprint); Tarakji Khaldoun (Reprint); Penn Marc S (Reprint); Lincoff A Michael (Reprint)
AUTHOR ADDRESS: The Cleveland Clinic Foundation, Cleveland, OH, USA**USA
JOURNAL: Journal of the American College of Cardiology 39 (5 Supplement A): p53A March 6, 2002 2002
MEDIUM: print
CONFERENCE/MEETING: 51st Annual Scientific Session of the American College of Cardiology Atlanta, GA, USA March 17-20, 2002; 20020317
ISSN: 0735-1097
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

5/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013681707 BIOSIS NO.: 200200275218
Platelet-leukocyte conjugates are increased in diabetic women compared to diabetic men with cardiovascular disease
AUTHOR: Tuttle Hillary (Reprint); Davis-Gorman Grace (Reprint); Copeland Jack (Reprint); McDonagh Paul (Reprint); Goldman Steve
AUTHOR ADDRESS: Univ of Arizona, Tucson, AZ, USA**USA
JOURNAL: Circulation 104 (17 Supplement): pII.320 October 23, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: Scientific Sessions 2001 of the American Heart Association Anaheim, California, USA November 11-14, 2001; 20011111
SPONSOR: American Heart Association
ISSN: 0009-7322
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

5/7/5 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

11454873 EMBASE No: 2002026373
Differential regulation of mouse kidney sodium-dependent transporters mRNA by cadmium
Tabatabai N.M.; Blumenthal S.S.; Lewand D.L.; Petering D.H.
S.S. Blumenthal, Department of Medicine, Medical College of Wisconsin, Zablocki Veterans Admin. Med. Center, 5000 West National Avenue, Milwaukee, WI 53295 United States
AUTHOR EMAIL: ssblumen@mcw.edu
Toxicology and Applied Pharmacology (TOXICOL. APPL. PHARMACOL.) (United States) 15 DEC 2001, 177/3 (163-173)
CODEN: TXAPA ISSN: 0041-008X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 30

Chronic exposure to cadmium can result in renal glycosuria. Previously, we reported that cadmium reduced the relative abundance of the sodium-glucose cotransporter mRNA (Blumenthal et al., Toxicol. Appl. Pharmacol. 149, 49-54, 1998). To investigate this phenomenon further, we isolated full-length cDNA clones encoding both high- and low-affinity sodium-dependent glucose transporters SGLT1 and SGLT2, respectively, from cultured mouse kidney cortical cells. We also amplified a fragment of another putative sodium-glucose cotransporter with homology to the known SAAT1/ ***pSGLT2*** or SGLT3 from our cultured cells and named it SGLT3. In

order to examine the effect of cadmium on these transporters, primary cultures of mouse kidney cortical cells were exposed to micromolar concentrations of cadmium for 24 h and levels of SGLT1, SGLT2, and SGLT3 mRNA were determined by semiquantitative RT-PCR. Five to 10 muM of cadmium inhibited sodium-dependent uptake of the glucose analog, alpha-methyl D-glucopyranoside and progressively reduced the level of SGLT1. Cadmium also inhibited SGLT2 mRNA by 37%, but no further decline was observed at concentrations of cadmium greater than 5 muM. While cadmium inhibited SGLT1 and SGLT2, it significantly stimulated the expression of SGLT3 by fivefold. These results imply that individual sodium-glucose cotransporter mRNA species are not regulated in a similar fashion. In addition, the isolation of three separate SGLT species from these cultures suggests that, in addition to SGLT1 and SGLT2, glucose reabsorption by renal epithelial cells might involve additional glucose transporters such as SGLT3. (c) 2001 Elsevier Science.

5/7/6 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

139035100 CA: 139(3)35100y PATENT
Methods and compositions for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses
INVENTOR(AUTHOR): Carter, Laura; Carreno, Beatriz; Lowe, Leslie D.; Whitters, Matthew J.; Dunussi, Kyri; Collins, Mary; Ma, Margery; Young, Deborah A.; Witek, Joann S.; Larsen, Glenn; Kasaian, Marion T.; Donaldson, Debra D.; Unger, Michelle
LOCATION: USA
ASSIGNEE: Wyeth, John, and Brother Ltd.
PATENT: U.S. Pat. Appl. Publ. ; US 20030108549 A1 DATE: 20030612
APPLICATION: US 264634 (20021004) *US 40005 (19980317) *US 560766 (20000428) *US 569384 (20000511) *US 972218 (20011004) *US PV373746 (20020417)
PAGES: 109 pp., Cont.-in-part of U.S. Ser. No. 972,218. CODEN: USXXCO
LANGUAGE: English CLASS: 424145100; A61K-039/395A; A61K-031/525B; A61K-031/4745B; A61K-031/415B
SECTION:
CA215005 Immunochemistry
CA201XXX Pharmacology
CA203XXX Biochemical Genetics
CA263XXX Pharmaceuticals
IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant immunostimulant, autoimmune disease cancer infection soluble IL21 receptor agonist antagonist
DESCRIPTORS:
Immunostimulants...
adjuvants; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Interleukin 12... Interleukin 15... Interleukin 17... Interleukin 18...
Tumor necrosis factors...
agonists and antagonists; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Spinal column,disease...
ankylosing spondylitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
anti-IL-21R; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
CD22(antigen)... CD4(antigen)...

antibodies; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Cytotoxic agents...
antimetabolites; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Dermatitis...
atopic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Thyroid gland,disease...
autoimmune thyroiditis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Estrogen receptors...
β agonist; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Drug delivery systems...
carriers; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Intestine,disease...
Crohn's; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
B cell(lymphocyte)...
depletion; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Lymphocyte...
effector cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Protein motifs...
extracellular domain; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
cDNA sequences...
for IL-21 receptor from human and mouse; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
fragments, anti-IL-21R; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
fragments; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
fusion products; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
humanized; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

infections
Mouse...
IL-21R/MU-1 from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Disease,animal...
immune cell-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Drug delivery systems...
immunoconjugates; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Neoplasm...
immunotherapy; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Drug delivery systems...
immunotoxins; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Parasite...
infection by; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Intestine,disease...
inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Cytokines... Enzymes,biological studies...
inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Diabetes mellitus...
insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Interleukin receptors...
interleukin-21, MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunotherapy... Autoimmune disease... Molecular cloning... Antitumor agents... Antimicrobial agents... Drug delivery systems... Allergy... Animal tissue culture... Anti-inflammatory agents... Arthritis... Asthma... B cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell... Cytotoxic agents... DNA sequences... Dermatitis... Drugs... Eczema... Genetic vectors... Human... Immunostimulants... Immunosuppressants... Leukemia... Lymphocyte... Lymphoma... Macrophage... Megakaryocyte... Multiple sclerosis... Myasthenia gravis... Osteoarthritis... Protein sequences... Psoriasis... Rheumatoid arthritis... T cell(lymphocyte)... Transplant rejection... Vaccines... Fusion proteins(chimeric proteins)... Growth inhibitors,animal... Immunoglobulin receptors... Immunoglobulins... Radionuclides,biological studies... Toxins...
interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Rheumatoid arthritis...
juvenile; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
T cell(lymphocyte)...
memory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
monoclonal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

infections
Lymphocyte...
natural killer cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
neutralizing; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Transcription factors...
NF-κB (nuclear factor of κ light chain gene enhancer in B-cells), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cance
Anti-inflammatory agents...
nonsteroidal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Selectins...
P-, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Glycoproteins...
PSGL-1 (P-selectin glycoprotein ligand-1), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Arthritis...
psoriatic arthritis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Proteins...
p38, inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Tumor necrosis factor receptors...
p55 and p75; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Connective tissue,disease...
scleroderma; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Molecules...
small; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Animal tissue,disease...
soft, neoplasm; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Neoplasm...
solid; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Lupus erythematosus...
systemic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Infection...
therapy; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Vaccines...
tumor; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antigens...
tumor-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Antigens...
tumor-assocd., RAGE; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antitumor agents...
vaccines; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Blood vessel,disease...
vasculitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Infection...
viral; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
CAS REGISTRY NUMBERS:
542817-54-9P 542817-58-3P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
9001-84-7 329900-75-6 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
140281-74-9 59-05-2 53123-88-9 75706-12-6 83869-56-1 162635-04-3 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
542817-53-8P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
542817-52-7DP 542817-56-1DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
542817-51-6DP 542817-55-0DP 542817-57-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
542820-51-9 542820-52-0 542820-53-1 542820-55-3 542820-56-4 542820-57-5 542820-58-6 542820-59-7 542820-60-0 542820-62-2 542820-64-4 542820-66-6 542820-68-8 542820-70-2 542820-72-4 542820-74-6 542820-76-8 542820-78-0 542820-79-1 542820-80-4 unclaimed nucleotide sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses
542820-50-8 542820-54-2 542820-61-1 542820-63-3 542820-65-5 542820-67-7 542820-69-9 542820-71-3 542820-73-5 542820-75-7 542820-77-9 unclaimed protein sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses
510729-85-8 434283-61-1 219312-69-3 138831-86-4 unclaimed sequence; methods and compns. for modulating interleukin-21 (IL-21) or IL-21 receptor (IL-21R) activity and therapeutic uses

5/7/7 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138302654 CA: 138(20)302654p PATENT
Interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
INVENTOR(AUTHOR): Carter, Laura; Whitters, Matthew J.; Collins, Mary; Young, Deborah A.; Larsen, Glenn; Donaldson, Debra D.; Lowe, Leslie D.; Dunussi, Kyri; Ma, Margery; Witek, Joann S.; Kasaian, Marion T.; Ungar, Michelle
LOCATION: USA
ASSIGNEE: Wyeth, John, and Brother Ltd.

PATENT: PCT International ; WO 200328630 A2 DATE: 20030410
APPLICATION: WO 2002US29839 (20021004) *US 972218 (20011004) *US PV373746 (20020417)
PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS ; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215005 Immunochemistry
CA201XXX Pharmacology
CA203XXX Biochemical Genetics
CA263XXX Pharmaceuticals
IDENTIFIERS: interleukin 21 receptor agonist antagonist immunosuppressant immunostimulant transplant rejection, autoimmune disease cancer infection soluble IL21 receptor agonist antagonist
DESCRIPTORS:
Immunostimulants...
adjuvants; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Tumor necrosis factors... Interleukin 12... Interleukin 15... Interleukin 17... Interleukin 18...
agonists and antagonists; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Spinal column,disease...
ankylosing spondylitis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
CD4(antigen)... CD22(antigen)...
antibodies; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Cytotoxic agents...
antimetabolites; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Dermatitis...
atopic; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Thyroid gland,disease...
autoimmune thyroiditis; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
A1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
A2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Infection...
bacterial; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Estrogen receptors...
β agonist; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

Drug delivery systems...
carriers; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
chimeric; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Intestine,disease...
Crohn's; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
D; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
B cell(lymphocyte)...
depletion; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
E; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Lymphocyte...
effector cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Protein motifs...
extracellular domain; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
fragments; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G2; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G2a; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G3; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
G4; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
humanized; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Disease,animal...
immune cell-assocd.; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Drug delivery systems...
immunoconjugates; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Drug delivery systems...
immunotoxins; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

infections
Intestine,disease...
inflammatory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Cytokines... Enzymes,biological studies...
inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Diabetes mellitus...
insulin-dependent; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunosuppressants... Lymphocyte... T cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell... B cell(lymphocyte)... Macrophage... Megakaryocyte... Transplant rejection... Autoimmune disease... Antigens... Vaccines... Immunostimulants... Antitumor agents... Infection... Parasite ... Immunotherapy... Multiple sclerosis... Arthritis... Rheumatoid arthritis... Myasthenia gravis... Dermatitis... Eczema... Psoriasis... Asthma... Allergy... Antibodies... Immunoglobulins... Toxins... Radionuclides,biological studies... Lymphoma... Leukemia... Parasitic worm ... Bacterium(genus)... Drugs... Growth inhibitors,animal... Anti-inflammatory agents... Cytotoxic agents... Human... Fusion proteins(chimeric proteins)... Osteoarthritis... Mammalia... Immunoglobulin receptors... Molecular cloning... DNA sequences... Protein sequences... Protozoa... Genetic vectors... Animal tissue culture... Immunoglobulin receptors...
interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Rheumatoid arthritis...
juvenile; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Immunoglobulins...
M; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Honeybee...
mellitin signal peptide from; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
T cell(lymphocyte)...
memory; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
monoclonal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Mouse... Rodentia...
MU-1; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Lymphocyte...
natural killer cell; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Antibodies...
neutralizing; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
Transcription factors...
NF-κB (nuclear factor of κ light chain gene enhancer in B-cells), inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cance
Anti-inflammatory agents...
nonsteroidal; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and

antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
CAS REGISTRY NUMBERS:
434283-61-1 amino acid sequence, signal peptide, included in fusion protein; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510729-85-8 amino acid sequence, STAT docking site, STAT5; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510788-28-0P 510787-86-7P 510788-32-6P 510788-34-8P 510788-36-0P 510788-38-2P 510788-40-6P 510788-42-8P 510788-44-0P amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
329900-75-6 9001-84-7 inhibitors; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
59-05-2 75706-12-6 53123-88-9 162635-04-3 83869-56-1 185243-69-0 140281-74-9 interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510787-85-6P 510788-27-9P 510788-31-5P 510788-33-7P 510788-35-9P 510788-37-1P 510788-39-3P 510788-41-7P 510788-43-9P nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510787-80-1DP 510787-84-5DP 510787-82-3DP subfragments are claimed, amino acid sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510786-18-2DP 510787-83-4DP 510787-81-2DP subfragments are claimed, nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510792-63-9 510792-64-0 510792-65-1 510792-70-8 510792-71-9 510792-72-0 510792-73-1 510792-74-2 510792-75-3 510792-78-6 510792-79-7 510792-80-0 unclaimed nucleotide sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510792-62-8 510792-66-2 510792-76-4 219312-69-3 138831-86-4 unclaimed protein sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections
510792-81-1 510792-82-2 unclaimed sequence; interleukin-21 receptor agonists and antagonists for treating transplant rejection, autoimmune diseases, cancers and infections

5/7/8 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

137179893 CA: 137(13)179893r PATENT
Methods for identifying compounds that inhibit or reduce PTP1B (protein tyrosine phosphatase 1B) expression
INVENTOR(AUTHOR): Zinker, Bradley A.; Trevillyan, James M.; Jirousek, Michael R.; Rondinone, Christina M.; Cowsert, Lex M.; Wyatt, Jacqueline; Monia, Brett P.; Butler, Madeline M.; Waring, Jeffrey French
LOCATION: USA
ASSIGNEE: Abbott Laboratories; Isis Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200264840 A2 DATE: 20020822
APPLICATION: WO 2002US4194 (20020213) *US PV268399 (20010213) *US 74194 (20020212)
PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A; C12N-015/11B; C12N-015/12B; C07K-014/47B; A01K-067/027B
DESIGNATED COUNTRIES: CA; JP; MX DESIGNATED REGIONAL: AT; BE; CH; CY; DE

; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR
SECTION:
CA201010 Pharmacology
IDENTIFIERS: protein tyrosine phosphatase 1B inhibitor identification, diabetes treatment protein tyrosine phosphatase 1B inhibitor
DESCRIPTORS:
Cyclins...
A, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase
Cytokines...
adiponectin, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinosito
Transport proteins...
amino acid-transporting, insulin-activated, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by d
Polynucleotides... Phosphorothioate oligodeoxyribonucleotides...
antisense; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Globins...
B, complex, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol
Adrenoceptors...
β3, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-
Cyclins...
B1, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinas
Proteins...
B2, complex, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinosito
Cyclins...
B2, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinas
Gene,animal...
c-abl, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Proteins...
c-Cbl-assocd. protein (CAP), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of pho
Gene,animal...
c-fms, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Gene,animal...
c-ros, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Chemokine receptors...
CCR1, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kin
CD antigens...
CD53, gene encoding, exon 7, as marker; methods for identifying

inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinosit
CD antigens...
CD72, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kin
Proteins...
cofilins, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3
Chemokines...
C10-like, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3
Proteins...
DBI (diazepam binding inhibitor), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection o
Proteins...
DEXRAS1 (ras-related protein), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of p
Chaperonins...
DnaJ, testes-specific, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphati
Cyclins...
D2, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinas
Proteins...
E3, retinoic acid inducible, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of pho
Proteins...
FABP (fatty acid-binding protein), gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection
Gene,animal...
Fas, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Lipids,biological studies...
formation, genes involved in, as markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinos
Proteins...
frataxin, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3
Gene,animal...
FSP27, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Peroxisome proliferator-activated receptors...
γ, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-
Thyrotropin receptors... Talin... Interleukin 1 receptor antagonist...
Profilins... CD44(antigen)... Entactin... Vimentins... Interleukin 6...
gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase is
Gluconeogenesis...

genes involved in, as markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kina
Gene,animal...
Glvr-1, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Genetic element...
GRE (glucocorticosteroid-responsive element), 16, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection
Proteins...
GTP-binding, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinosito
G proteins(guanine nucleotide-binding proteins)...
G11, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kina
Gene,animal...
HAM1, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Immunoglobulins...
heavy chains, VDJ region, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosph
Gene,animal...
HSL, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
Proteins...
human hematopoietic specific protein 1, gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of pho
Proteins...
interferon γ inducible protein 47, gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of ph
Proteins...
interferon-induced 15 kDa protein, gene encoding, as marker; identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphati
Proteins...
interferon-induced, 6-16, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosph
Proteins...
IRS-2 (insulin receptor substrate 2), marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidyl
Transcription factors...
ISGF-7 (interferon-stimulated gene factor 7), gene encoding; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection
Antigens...
lymphocyte differentiation, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phos
Mannose receptors...
macrophage, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol
Drug screening... Adipose tissue... Liver... Mammalia... Mouse... Rat...

Monkey... Chimpanzee... Dog(Canis familiaris)... Cattle... Proteins...
Organic compounds,biological studies... Polysaccharides,biological studies
... Oligonucleotides... Polynucleotides... Antisense oligonucleotides...
Antidiabetic agents... Obesity...
    methods for identifying inhibitors of protein tyrosine phosphatase 1B
    expression in insulin resistant obese non-human mammals by detection of
    phosphatidylinositol-3-kinase isoforms
Proteins...
    mitochondrial matrix protein 1, gene encoding; methods for identifying
    inhibitors of protein tyrosine phosphatase 1B expression in insulin
    resistant obese non-human mammals by detection of phosphatidy
Proteins...
    monocyte activating polypeptide 1, gene encoding; methods for
    identifying inhibitors of protein tyrosine phosphatase 1B expression in
    insulin resistant obese non-human mammals by detection of phosphat
Proteins...
    Mo54 (mouse protective protein 54), gene encoding, as marker;
    identifying inhibitors of protein tyrosine phosphatase 1B expression in
    insulin resistant obese non-human mammals by detection of phosphat
Gene,animal...
    mTRP1, beta variant, as marker; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-kin
Proteins...
    neuronatin, gene encoding, as marker; methods for identifying
    inhibitors of protein tyrosine phosphatase 1B expression in insulin
    resistant obese non-human mammals by detection of phosphatidylinositol
Diabetes mellitus...
    non-insulin-dependent, treatment; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-k
Gene,animal...
    of gluconeogenesis, as marker; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-kina
Gene,animal...
    of lipogenesis, as marker; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-kinase i
Peptides,biological studies...
    oligopeptides; methods for identifying inhibitors of protein tyrosine
    phosphatase 1B expression in insulin resistant obese non-human mammals
    by detection of phosphatidylinositol-3-kinase isoforms
Proteins...
    Osteogenesis inperfecta (Ddt), gene encoding, as marker; methods for
    identifying inhibitors of protein tyrosine phosphatase 1B expression in
    insulin resistant obese non-human mammals by detection of p
Proteins...
    Ott, gene encoding, as marker; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-kina
Transcription factors...
    PAN2, gene encoding, as marker; methods for identifying inhibitors of
    protein tyrosine phosphatase 1B expression in insulin resistant obese
    non-human mammals by detection of phosphatidylinositol-3-kin
(etc.)...
  CAS REGISTRY NUMBERS:
9024-52-6 A, gene encoding, as marker; methods for identifying inhibitors
    of protein tyrosine phosphatase 1B expression in insulin resistant
    obese non-human mammals by detection of phosphatidylinositol-3-kinase
    isoforms
50-99-7 biological studies, blood, agents for decrease of; methods for
    identifying inhibitors of protein tyrosine phosphatase 1B expression in
    insulin resistant obese non-human mammals by detection of

phosphatidylinositol-3-kinase isoforms
9004-10-8 biological studies, resistance; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9014-34-0 50812-37-8 9045-77-6 9029-96-3 9004-02-8 9027-95-6 9001-04-1 9075-65-4 9014-19-1 9077-14-9 9013-08-5 9028-47-1 9013-18-7 37213-56-2 140208-23-7 9001-52-9 9001-39-2 162874-99-9 80295-40-5 56941-20-9 37256-73-8 9054-65-3 184111-06-6 9026-39-5 60267-61-0 9047-22-7 9025-26-7 94716-09-3 171715-12-1 141467-20-1 165245-94-3 69106-44-1 9014-43-1 180983-98-6 147014-97-9 156229-84-4 gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9036-21-9 isoform A, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9001-60-9 isoform B, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9000-96-8 liver, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9004-06-2 metallo-, macrophage, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
300865-11-6 350267-87-7 142243-03-6 methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9027-13-8 9054-54-0 mitochondrial, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
71965-46-3 80295-33-6 precursor, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
115926-52-8 p50α and p55α and p85α isoforms, markers; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9002-02-2 9035-42-1 9001-97-2 similar, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
449828-25-5 449828-26-6 449828-27-7 449828-28-8 449828-29-9 449828-30-2 449828-31-3 449828-32-4 449828-33-5 449828-34-6 449828-35-7 449828-36-8 449828-37-9 449834-74-6 unclaimed nucleotide sequence; methods for identifying compds. that inhibit or reduce PTP1B (protein tyrosine phosphatase 1B) expression
9000-83-3 vacuolar, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
37205-61-1 venom basic 1, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

9028-86-8 9027-03-6 2, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9013-02-9 139691-92-2 2, mitochondrial, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms
9012-42-4 7, gene encoding, as marker; methods for identifying inhibitors of protein tyrosine phosphatase 1B expression in insulin resistant obese non-human mammals by detection of phosphatidylinositol-3-kinase isoforms

5/7/9 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133280563 CA: 133(20)280563a PATENT
Human antibodies that bind human IL-12 and methods for producing
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael; Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra; Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela; Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela; Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara; Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.
LOCATION: Germany,
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928
APPLICATION: WO 2000US7946 (20000324) *US PV126603 (19990325)
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A; C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B; G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL ; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215003 Immunochemistry
CA203XXX Biochemical Genetics
IDENTIFIERS: human antibody interleukin 12 autoimmune disease, inflammation recombinant antibody human interleukin 12
DESCRIPTORS:
Immunoglobulins...
A; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Respiratory distress syndrome...
adult; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Interleukin 2 receptors...
α-chain; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Spinal column...
ankylosing spondylitis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Transforming growth factors...
β-; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Interferons...
β1, β1a and β1b; recombinant human antibodies that bind

human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Phytohemagglutinins...
blast proliferation assay; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Drug delivery systems...
carriers; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Antigens...
CD90; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Fatigue,biological...
chronic fatigue syndrome; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
conjugates; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Intestine,disease...
Crohn's; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Anti-inflammatory agents...
cytokine; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunity...
disorder, acute and chronic; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Blood coagulation...
disseminated intravascular; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
E; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Cytokines...
EMAP-II or endothelial-monocyte-activating polypeptide II; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Heart,disease...
failure; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Lung,disease...
fibrosis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
fragments; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Transplant and Transplantation...
graft-vs.-host reaction; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
G1; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
G2; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
G3; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
G4; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
heavy chains; recombinant human antibodies that bind human IL-12 for

treatment of autoimmune diseases and inflammatory diseases
Anemia(disease)...
hemolytic; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Purpura(disease)...
Henoch-Schoenlein's; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Nervous system...
Huntington's chorea; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Tumor necrosis factor receptors...
Ig conjugates; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Heart,disease...
infarction; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Parasite...
infection; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Cytokines...
inflammatory, anti-; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Intestine,disease...
inflammatory; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Complement... Signal transduction,biological... Thromboxanes...
inhibitors; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Drug delivery systems...
injections, i.v.; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Diabetes mellitus...
insulin-dependent; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Baboon... Chimpanzee... Macaca irus... Macaca mulatta... Marmoset...
Primate...
interleukin 12; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Rheumatoid arthritis...
juvenile; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Blood vessel,disease...
Kawasaki; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
light chains; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Immunoglobulins...
M; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Antibodies...
monoclonal; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Spinal cord...
myelitis, acute transverse; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Kidney,disease...
nephrotic syndrome; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Antibodies...
neutralizing; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Anti-inflammatory agents...

nonsteroidal; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Selectins...
P-, glycoprotein ligand; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Glycoproteins,specific or class...
p-selectin glycoprotein ligand; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Artery,disease...
periarteritis nodosa; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Bioassay...
phytohemagglutinin blast proliferation assay; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Biliary tract...
primary biliary cirrhosis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
Arthritis...
psoriatic arthritis; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
(etc.)...
CAS REGISTRY NUMBERS:
80700-82-9 135343-43-0 145001-20-3 148325-41-1 148325-45-5 148325-49-9 156656-32-5 250282-12-3 250282-13-4 250714-30-8 250714-33-1 253143-79-2 269048-31-9 297776-78-4 297776-79-5 297776-80-8 297776-81-9 297776-82-0 297776-83-1 297776-84-2 297776-85-3 297776-86-4 297776-87-5 297776-88-6 297776-89-7 297776-90-0 297776-91-1 297776-92-2 297776-93-3 297776-94-4 297776-95-5 297776-96-6 297776-97-7 297776-98-8 297776-99-9 297777-00-5 297777-01-6 297777-02-7 297777-03-8 297777-04-9 297777-05-0 297777-06-1 297777-07-2 297777-08-3 297777-09-4 297777-10-7 297777-11-8 297777-12-9 297777-13-0 297777-14-1 297777-15-2 297777-16-3 297777-17-4 297777-18-5 297777-19-6 297777-20-9 297777-21-0 297777-22-1 297777-23-2 297777-24-3 297777-25-4 297777-26-5 297777-27-6 297777-28-7 297777-29-8 297777-30-1 297777-31-2 297777-32-3 297777-33-4 297777-34-5 297777-35-6 amino acid sequence; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
28088-64-4D analogs, recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
58-61-7 biological studies, agonists; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
7782-44-7 biological studies, hyperbaric; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
110-86-1D imidazole compds., recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
80449-02-1 142243-02-5 inhibitor; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
9004-06-2 9015-82-1 9025-82-5 9029-60-1 122191-40-6 151769-16-3 inhibitors; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
9036-21-9 IV, inhibitor; recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
288-32-4D pyridinyl compds., recombinant human antibodies that bind human IL-12 for treatment of autoimmune diseases and inflammatory diseases
50-02-2 50-18-0 50-24-8 50-44-2 59-05-2 83-43-2 89-57-6 443-48-1 446-86-6 504-24-5 599-79-1 4291-63-8 15687-27-1 15722-48-2 51322-75-9 51333-22-3 53123-88-9 62031-54-3 62229-50-9 75706-12-6 79217-60-0 80573-04-2 83869-56-1 104987-11-3 128794-94-5

147245-92-9 159606-08-3 167397-96-8 188596-65-8 260430-71-5
260430-72-6 297736-18-6 297736-19-7 297736-20-0 297736-21-1
297736-22-2 297736-23-3 297736-24-4 297738-05-7 297738-06-8
297738-07-9 297738-08-0 297738-09-1 297738-10-4 297738-11-5
297738-12-6 297738-13-7 297738-14-8 297738-15-9 297738-16-0
297738-17-1 297738-18-2 297738-19-3 297738-20-6 297738-21-7
297738-22-8 297738-23-9 297738-24-0 297738-25-1 297738-26-2
297738-27-3 297738-28-4 297738-29-5 297738-30-8 297738-31-9
297738-32-0 297738-33-1 297738-34-2 297738-35-3 297738-36-4
297738-37-5 297738-38-6 297738-39-7 297738-40-0 297738-41-1
297738-42-2 297738-43-3 297738-44-4 297738-45-5 297738-46-6
297738-47-7 297738-48-8 297738-49-9 297738-50-2 297738-51-3
297738-52-4 297738-53-5 297738-54-6 297738-55-7 297738-56-8
297738-57-9 297738-58-0 297738-59-1 297738-60-4 297738-61-5
297738-62-6 297738-63-7 297738-64-8 297738-65-9 297738-66-0
297738-67-1 297738-68-2 297738-69-3 297738-70-6 297738-71-7
297738-72-8 297738-73-9 297738-74-0 297738-75-1 297738-76-2
297738-77-3 297738-78-4 297738-79-5 297738-80-8 297738-81-9
297738-82-0 297738-83-1 297738-84-2 297738-85-3 297738-86-4
297738-87-5 297738-88-6 297738-89-7 297738-90-0 297738-91-1
297738-92-2 297738-93-3 297738-94-4 297738-95-5 297738-96-6
297738-97-7 297738-98-8 297738-99-9 297739-00-5 297739-01-6
297739-02-7 297739-03-8 297739-04-9 297739-05-0 297739-06-1
297739-07-2 297739-08-3 297739-09-4 297739-10-7 297739-11-8
297739-12-9 297739-13-0 297739-14-1 297739-15-2 297739-16-3
297739-17-4 297739-18-5 297739-19-6 297739-20-9 297739-21-0
297739-22-1 297739-23-2 297739-24-3 297739-25-4 297739-26-5
297739-27-6 297739-28-7 297739-29-8 297739-30-1 297739-31-2
297739-32-3 297739-33-4 297739-34-5 297739-35-6 297739-36-7
297739-37-8 297739-38-9 297739-39-0 297739-40-3 297739-41-4
297739-42-5 297739-43-6 297739-44-7 297739-45-8 297739-46-9
297739-47-0 297739-48-1 297739-49-2 297739-50-5 297739-51-6
297739-52-7 297739-53-8 297739-54-9 297739-55-0 297739-56-1
297739-57-2 297739-58-3 297739-59-4 297739-60-7 297739-61-8
297739-62-9 297739-63-0 297739-64-1 297739-65-2 297739-66-3
297739-67-4 297739-68-5 297739-69-6 297739-70-9 297739-71-0
297739-72-1 297739-73-2 297739-74-3 297739-75-4 297739-76-5
297739-77-6 297739-78-7 297739-79-8 297739-80-1 297739-81-2
297739-82-3 297739-83-4 297739-84-5 297739-85-6 297739-86-7
297739-87-8 297739-88-9 297739-89-0 297739-90-3 297739-91-4
297739-92-5 297739-93-6 297739-94-7 297739-95-8 297739-96-9
297739-97-0 297739-98-1 297739-99-2 297740-00-2 297740-01-3
297740-02-4 297740-03-5 297740-04-6 297740-05-7 297740-06-8
297740-07-9 297740-08-0 297740-09-1 297740-10-4 297740-11-5
297740-12-6 297740-13-7 297740-14-8 297740-15-9 297740-16-0
297740-17-1 297740-18-2 297740-19-3 297740-20-6 297740-21-7
297740-22-8 297740-23-9 297740-24-0 297740-25-1 297740-26-2
297740-27-3 297740-28-4 297740-29-5 297740-30-8 297740-31-9
297740-32-0 297740-33-1 297740-34-2 297740-35-3 297740-36-4
297740-37-5 297740-38-6 297740-39-7 297740-40-0 297740-41-1
297740-42-2 297740-43-3 297740-44-4 297740-45-5 297740-46-6
297740-47-7 297740-48-8 297740-49-9 297740-50-2 297740-51-3
297740-52-4 297740-53-5 297740-54-6 297740-55-7 297740-56-8
297740-57-9 297740-58-0 297740-59-1 297740-60-4 297740-61-5
297740-62-6 297740-63-7 297740-64-8 297740-65-9 297740-66-0
297740-67-1 297740-68-2 298200-40-5 298200-41-6 298200-42-7
298200-43-8 298200-44-9 298200-45-0 298200-46-1 298200-47-2
298200-48-3 298200-49-4 298200-50-7 recombinant human antibodies
that bind human IL-12 for treatment of autoimmune diseases and
inflammatory diseases
226983-90-0 226984-98-1 297782-45-7 297782-46-8 297782-47-9
297782-48-0 297782-49-1 297782-50-4 297782-51-5 unclaimed
nucleotide sequence; human antibodies that bind human IL-12 and methods
for producing

260430-73-7 297782-22-0 297782-23-1 297782-24-2 297782-25-3
297782-26-4 297782-27-5 297782-28-6 297782-29-7 297782-30-0
297782-31-1 297782-32-2 297782-33-3 297782-34-4 297782-35-5
297782-36-6 297782-37-7 297782-38-8 297782-39-9 297782-40-2
297782-41-3 297782-42-4 297782-43-5 297782-44-6 297782-52-6
297782-53-7 298200-51-8 298200-52-9 298200-53-0 unclaimed protein sequence; human antibodies that bind human IL-12 and methods for producing
297736-25-5 297736-26-6 297736-27-7 297736-28-8 297736-29-9
297736-30-2 297736-31-3 297736-32-4 297736-33-5 297736-34-6
297736-35-7 297736-36-8 297736-37-9 297736-38-0 297736-39-1
297736-40-4 297736-41-5 297736-42-6 297736-43-7 297736-44-8
297736-45-9 297736-46-0 297736-47-1 297736-48-2 297736-49-3
297736-50-6 297736-51-7 297736-52-8 297736-53-9 297736-54-0
297736-55-1 297736-56-2 297736-57-3 297736-58-4 297736-59-5
297736-60-8 297736-61-9 297736-62-0 297736-63-1 297736-64-2
297736-65-3 297736-66-4 297736-67-5 297736-68-6 297736-69-7
297736-70-0 297736-71-1 297736-72-2 297736-73-3 297736-74-4
297736-75-5 297736-76-6 297736-77-7 297736-78-8 297736-79-9
297736-80-2 297736-81-3 297736-82-4 297736-83-5 297736-84-6
297736-85-7 297736-86-8 297736-87-9 297736-88-0 297736-89-1
297736-90-4 297736-91-5 297736-92-6 297736-93-7 297736-94-8
297736-95-9 297736-96-0 297736-97-1 297736-98-2 297736-99-3
297737-00-9 297737-01-0 297737-02-1 297737-03-2 297737-04-3
297737-05-4 297737-06-5 297737-07-6 297737-08-7 297737-09-8
297737-10-1 297737-11-2 297737-12-3 297737-13-4 297737-14-5
297737-15-6 297737-16-7 297737-17-8 297737-18-9 297737-19-0
297737-20-3 297737-21-4 297737-22-5 297737-23-6 297737-24-7
297737-25-8 297737-26-9 297737-27-0 297737-28-1 297737-29-2
297737-30-5 297737-32-7 297737-33-8 297737-34-9 297737-35-0
297737-36-1 297737-37-2 297737-38-3 297737-39-4 297737-40-7
297737-41-8 297737-42-9 297737-43-0 297737-44-1 297737-45-2
297737-46-3 297737-47-4 297737-48-5 297737-49-6 297737-50-9
297737-51-0 297737-52-1 297737-53-2 297737-54-3 297737-55-4
297737-56-5 297737-57-6 297737-58-7 297737-59-8 297737-60-1
297737-61-2 297737-62-3 297737-63-4 297737-64-5 297737-65-6
297737-66-7 297737-67-8 297737-68-9 297737-69-0 297737-70-3
297737-71-4 297737-72-5 297737-73-6 297737-74-7 297737-75-8
297737-76-9 297737-77-0 297737-78-1 297737-79-2 297737-80-5
297737-81-6 297737-82-7 297737-83-8 297737-84-9 297737-85-0
297737-86-1 297737-87-2 297737-88-3 297737-89-4 297737-90-7
297737-91-8 297737-92-9 297737-93-0 297737-94-1 297737-95-2
297737-96-3 297737-97-4 297737-98-5 297737-99-6 297738-00-2
297738-01-3 297738-02-4 297738-03-5 297738-04-6 unclaimed sequence; human antibodies that bind human IL-12 and methods for producing

5/7/10 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

131285285 CA: 131(21)285285e JOURNAL
Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice
AUTHOR(S): Trembleau, Sylvie; Penna, Giuseppe; Gregori, Silvia; Chapman, Harold D.; Serreze, David V.; Magram, Jeanne; Adorini, Luciano
LOCATION: Roche Milano Ricerche, Milan, Italy
JOURNAL: J. Immunol. DATE: 1999 VOLUME: 163 NUMBER: 5 PAGES: 2960-2968 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English PUBLISHER: American Association of Immunologists
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: diabetes Th1 lymphocyte interleukin 12 deficiency
DESCRIPTORS:

```
Interferons...
    γ; lipopolysaccharide-induced, of pancreas-infiltrating CD4+ T
    cells in wild-type and IL-12-deficient nonobese diabetic mice
T cell(lymphocyte)...
    helper cell/inducer, TH1; pancreas-infiltrating Th1 cells and diabetes
    develop in IL-12-deficient nonobese diabetic mice
Diabetes mellitus...
    insulin-dependent; pancreas-infiltrating Th1 cells and diabetes develop
    in IL-12-deficient nonobese diabetic mice
Pancreatic islet of Langerhans...
    insulitis; pancreas-infiltrating Th1 cells and diabetes develop in
    IL-12-deficient nonobese diabetic mice
CD4-positive T cell... Interleukin 12... Pancreatic islet of Langerhans...
    pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient
    nonobese diabetic mice
Glycoproteins,specific or class...
    PSGL-1 (P-selectin glycoprotein ligand-1); of pancreas-infiltrating
    CD4+ T cells in wild-type and IL-12-deficient nonobese diabetic mice
? t s5/kwic/9,10
>>>KWIC option is not available in file(s): 399
? ds

Set     Items   Description
S1         33   E1-E3
S2         13   E2-E7
S3          0   S(1 OR S2) AND (PSGL?)
S4         15   (PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABE-
              TES)
S5         10   RD S4 (unique items)
? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand)(10n)(antibod?) and (autoimmun?
or diabetes)
           1291  PSGL?
        4542066  P
          33878  SELECTIN
         291626  GLYCOPROTEIN
         384590  LIGAND
           1323  P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND
        1896131  ANTIBOD?
            276  (PSGL? OR
                 P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)ANTIBOD?
         221473  AUTOIMMUN?
         589096  DIABETES
     S6      11  (PSGL? OR
                 P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND
                 (AUTOIMMUN? OR DIABETES)
? rd s6
...completed examining records
     S7      10  RD S6 (unique items)
? t s7/3/all

 7/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014345912   BIOSIS NO.: 200300303401
CD8+ T cells from patients with acute multiple sclerosis display selective
  increase of adhesiveness in brain venules: A critical role for P-selectin
  glycoprotein ligand-1.
AUTHOR: Battistini Luca; Piccio Laura; Rossi Barbara; Bach Simona; Galgani
  Simona; Gasperini Claudio; Ottoboni Linda; Ciabini Donatella; Caramia
  Maria D; Bernardi Giorgio; Laudanna Carlo; Scarpini Elio; McEver Rodger P
  ; Butcher Eugene C; Borsellino Giovanna; Constantin Gabriela (Reprint)
AUTHOR ADDRESS: Department of Pathology, Division of General Pathology,
  University of Verona, Strada le Grazie 8, Verona, 37134, Italy**Italy
```

AUTHOR E-MAIL ADDRESS: gabriela.constantin@univr.it
JOURNAL: Blood 101 (12): p4775-4782 June 15, 2003 2003
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

7/3/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

12182227 EMBASE No: 2003289054
CD8SUP+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1
Battistini L.; Piccio L.; Rossi B.; Bach S.; Galgani S.; Gasperini C.; Ottoboni L.; Ciabini D.; Caramia M.D.; Bernardi G.; Laudanna C.; Scarpini E.; McEver R.P.; Butcher E.C.; Borsellino G.; Constantin G.
G. Constantin, Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona 37134 Italy
AUTHOR EMAIL: gabriela.constantin@univr.it
Blood (BLOOD) (United States) 15 JUN 2003, 101/12 (4775-4782)
CODEN: BLOOA ISSN: 0006-4971
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

7/3/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092589 CA: 140(7)92589j PATENT
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108
APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/4 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092584 CA: 140(7)92584d PATENT
Methods for therapeutic treatment utilizing sub-clinical amount of a therapeutic agent combined with or conjugated to an antibody, or fragment thereof

INVENTOR(AUTHOR): Lazarovits, Janette; Nimrod, Abraham; Hoch-Mar-Chaim, Hagit; Levanon, Avigdor
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200402528 A1 DATE: 20040108
APPLICATION: WO 2003US20604 (20030630) *US 189025 (20020701)
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; A61K-051/00B; A61K-038/00B; A61K-039/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM ; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/5 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092576 CA: 140(7)92576c PATENT
Antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101
APPLICATION: US 32423 (20011231) *US PV258948 (20001229)
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B; C07K-014/16B; C07K-007/08B; C07K-007/06B

7/3/6 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140075946 CA: 140(6)75946f PATENT
Multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof
INVENTOR(AUTHOR): Levanon, Avigdor; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Lazarovits, Janette
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040001839 A1 DATE: 20040101
APPLICATION: US 29988 (20011231) *US PV258948 (20001229)
PAGES: 149 pp., Cont.-in-part of U.S. Provisonal Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English CLASS: 424178100; A61K-039/395A; C07K-014/46B

7/3/7 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138152275 CA: 138(11)152275z PATENT
Modulators of P-selectin glycoprotein ligand 1
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling
LOCATION: Taiwan,

ASSIGNEE: Abgenomics Co.
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220
APPLICATION: WO 2002US7498 (20020313) *US PV310196 (20010803) *US 51497 (20020118)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/8 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

137108286 CA: 137(8)108286j PATENT
Antibodies and fragments against epitopes present on cancer, metastatic or leukemia cells and platelets for diagnosis and therapy of tumor, metastasis, leukemia, autoimmune disease, and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagai, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Kooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: USA
ASSIGNEE: Bio-Technology General Corp.
PATENT: PCT International ; WO 200253700 A2 DATE: 20020711
APPLICATION: WO 2001US49442 (20011231) *US 751181 (20001229) *US PV258948 (20001229)
PAGES: 310 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

7/3/9 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

133280563 CA: 133(20)280563a PATENT
Human antibodies that bind human IL-12 and methods for producing
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael; Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra; Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela; Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela; Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara; Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.
LOCATION: Germany,
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928
APPLICATION: WO 2000US7946 (20000324) *US PV126603 (19990325)
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A; C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B; G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL ; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM;

```
DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP;
KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL;
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN;
YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  DESIGNATED REGIONAL: GH; GM
; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR;
GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;
MR; NE; SN; TD; TG


 7/3/10     (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

  132303492    CA: 132(23)303492x    PATENT
  Inhibition of differentiation of T-cells to cytotoxic lymphocytes by
P-selectin ligand (PSGL) antagonists
  INVENTOR(AUTHOR): Manjunath, Narasimhaswamy; Hans Von Andrian, Ulrich
  LOCATION: USA
  ASSIGNEE: Genetics Institute, Inc.; CBR Laboratories, Inc.
  PATENT: PCT International ; WO 200025808 A1  DATE: 20000511
  APPLICATION: WO 99US25501 (19991029) *US PV106315 (19981030)
  PAGES: 66 pp.  CODEN: PIXXD2  LANGUAGE: English  CLASS: A61K-038/16A;
A61K-038/17B  DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;
CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;
IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN;
MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA;
UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
  DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE;
CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF;
CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
? ds

Set     Items   Description
S1         33   E1-E3
S2         13   E2-E7
S3          0   S(1 OR S2) AND (PSGL?)
S4         15   (PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABE-
              TES)
S5         10   RD S4 (unique items)
S6         11   (PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIB-
              OD?) AND (AUTOIMMUN? OR DIABETES)
S7         10   RD S6 (unique items)
? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand)(10n)(antibod?) and (apoptosis)
          1291  PSGL?
       4542066  P
         33878  SELECTIN
        291626  GLYCOPROTEIN
        384590  LIGAND
          1323  P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND
       1896131  ANTIBOD?
           276  (PSGL? OR
                P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)ANTIBOD?
        323263  APOPTOSIS
    S8       6  (PSGL? OR
                P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND
                (APOPTOSIS)
? rd s8
...completed examining records
    S9       5  RD S8 (unique items)
? t s9/3/all

 9/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.
```

0013667939 BIOSIS NO.: 200200261450
Adhesion to E-selectin promotes growth inhibition and **apoptosis** of human and murine hematopoietic progenitor cells
AUTHOR: Winkler Ingrid G (Reprint); Eto Tetsuya (Reprint); Purton Louise E (Reprint); Haylock David N (Reprint); Snapp Karen R; Kansas Geoffrey S; Simmons Paul J (Reprint); Levesque Jean-Pierre (Reprint)
AUTHOR ADDRESS: Stem Cell Biology Laboratory, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia**Australia
JOURNAL: Blood 98 (11 Part 1): p797a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012251034 BIOSIS NO.: 199900510694
PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in suppression of hematopoiesis
AUTHOR: Levesque Jean-Pierre; Zannettino Andrew C W; Pudney Melanie; Niutta Silvana; Haylock David N; Snapp Karen R; Kansas Geoffrey S; Berndt Michael C; Simmons Paul J (Reprint)
AUTHOR ADDRESS: Hanson Centre for Cancer Research, Matthew Roberts Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA, 5000, Australia**Australia
JOURNAL: Immunity 11 (3): p369-378 Sept., 1999 1999
MEDIUM: print
ISSN: 1074-7613
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092589 CA: 140(7)92589j PATENT
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108
APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;

BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/3/4 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092576 CA: 140(7)92576c PATENT
Antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation
INVENTOR(AUTHOR): Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
LOCATION: Israel
PATENT: U.S. Pat. Appl. Publ. ; US 20040002450 A1 DATE: 20040101
APPLICATION: US 32423 (20011231) *US PV258948 (20001229)
PAGES: 155 pp., Cont.-in-part of U.S. Provisional Ser. No. 258,948.
CODEN: USXXCO LANGUAGE: English CLASS: 514012000; A61K-038/16A; A61K-038/10B; A61K-038/08B; C07K-014/16B; C07K-007/08B; C07K-007/06B

9/3/5 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

138152275 CA: 138(11)152275z PATENT
Modulators of P-selectin glycoprotein ligand 1
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling
LOCATION: Taiwan,
ASSIGNEE: Abgenomics Co.
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220
APPLICATION: WO 2002US7498 (20020313) *US PV310196 (20010803) *US 51497 (20020118)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)

? s (psgl? or p(w)selectin(W)glycoprotein(W)ligand)(10n)(antibod?) and (t(W)cell? or t(w)lymphocyt? or nk or natural(W)killer)
Processing
Processing
Processing

```
Processing
Processing
           1291  PSGL?
        4542066  P
          33878  SELECTIN
         291626  GLYCOPROTEIN
         384590  LIGAND
           1323  P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND
        1896131  ANTIBOD?
            276  (PSGL? OR
                 P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)ANTIBOD?
        4812141  T
       10596180  CELL?
         621976  T(W)CELL?
        4812141  T
        1184902  LYMPHOCYT?
         439095  T(W)LYMPHOCYT?
          69730  NK
        1034538  NATURAL
         119554  KILLER
          89342  NATURAL(W)KILLER
     S10      42  (PSGL? OR
                 P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND
                 (T(W)CELL? OR T(W)LYMPHOCYT? OR NK OR NATURAL(W)KILLER)
? rd s10
...completed examining records
     S11      20  RD S10 (unique items)
? s s11 and apoptosis
           20  S11
       323263  APOPTOSIS
     S12       2  S11 AND APOPTOSIS
? t s12/3/all

 12/3/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

  140092589    CA: 140(7)92589j    PATENT
  Antibodies or scFv fragments specific to PSGL-1 epitopes useful for
diagnosis, prognosis and treatment of cancer, inflammation, infection,
autoimmune disease, metastasis and leukemia
  INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel;
Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
  LOCATION: USA
  ASSIGNEE: Savient Pharmaceuticals, Inc.
  PATENT: PCT International ; WO 200403166 A2  DATE: 20040108
  APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
  PAGES: 106 pp.  CODEN: PIXXD2  LANGUAGE: English  CLASS: C12N-000/A
  DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG


 12/3/2     (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

  138152275    CA: 138(11)152275z    PATENT
```

Modulators of P-selectin glycoprotein ligand 1
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling
LOCATION: Taiwan,
ASSIGNEE: Abgenomics Co.
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220
APPLICATION: WO 2002US7498 (20020313) *US PV310196 (20010803) *US 51497 (20020118)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)
S10	42	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (T(W)CELL? OR T(W)LYMPHOCYT? OR NK OR NATURAL(W)KILLER)
S11	20	RD S10 (unique items)
S12	2	S11 AND APOPTOSIS

? t s11/3/all

11/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014396997 BIOSIS NO.: 200300355716
The role of selectins in inflammation and disease.
AUTHOR: Ley Klaus (Reprint)
AUTHOR ADDRESS: Cardiovascular Research Center and Departments of Biomedical Engineering, Molecular Physiology and Biological Physics, University of Virginia, MR5 Building, Room 1013, PO Box 801394, Charlottesville, VA, 22908-1394, USA**USA
AUTHOR E-MAIL ADDRESS: klausley@virginia.edu
JOURNAL: Trends in Molecular Medicine 9 (6): p263-268 June 2003 2003
MEDIUM: print
ISSN: 1471-4914 _(ISSN print)
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

11/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014345912 BIOSIS NO.: 200300303401

CD8+ **T cells** from patients with acute multiple sclerosis
display selective increase of adhesiveness in brain venules: A critical
role for P-selectin glycoprotein ligand-1.
AUTHOR: Battistini Luca; Piccio Laura; Rossi Barbara; Bach Simona; Galgani
Simona; Gasperini Claudio; Ottoboni Linda; Ciabini Donatella; Caramia
Maria D; Bernardi Giorgio; Laudanna Carlo; Scarpini Elio; McEver Rodger P
; Butcher Eugene C; Borsellino Giovanna; Constantin Gabriela (Reprint)
AUTHOR ADDRESS: Department of Pathology, Division of General Pathology,
University of Verona, Strada le Grazie 8, Verona, 37134, Italy**Italy
AUTHOR E-MAIL ADDRESS: gabriela.constantin@univr.it
JOURNAL: Blood 101 (12): p4775-4782 June 15, 2003 2003
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0014116452 BIOSIS NO.: 200300075171
Glycosylation-dependent inhibition of cutaneous lymphocyte-associated
antigen expression: Implications in modulating lymphocyte migration to
skin.
AUTHOR: Dimitroff Charles J; Bernacki Ralph J; Sackstein Robert (Reprint)
AUTHOR ADDRESS: Harvard Institutes of Medicine, 77 Ave Louis Pasteur, Room
671, Boston, MA, 02115, USA**USA
AUTHOR E-MAIL ADDRESS: rsackstein@rics.bwh.harvard.edu
JOURNAL: Blood 101 (2): p602-610 January 15, 2003 2003
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0014080818 BIOSIS NO.: 200300049537
Characterisation of adhesion receptors mediating lymphocyte adhesion to
bronchial endothelium provides evidence for a distinct lung homing
pathway.
AUTHOR: Ainslie M P; McNulty C A; Huynh T; Symon F A; Wardlaw A J (Reprint)
AUTHOR ADDRESS: Department of Respiratory Medicine, Glenfield Hospital,
Groby Road, Leicester, LE3 9QP, UK**UK
AUTHOR E-MAIL ADDRESS: aw24@le.ac.uk
JOURNAL: Thorax 57 (12): p1054-1059 December 2002 2002
MEDIUM: print
ISSN: 0040-6376
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013396971 BIOSIS NO.: 200100568810
Tonsillar B cells do not express PSGL-1, but a significant fraction

displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity
AUTHOR: Armerding Dieter (Reprint); Fuhlbrigge Robert C; Kieffer J David; Kupper Thomas S
AUTHOR ADDRESS: Donaustrasse 73, A-3421, Hoeflein an der Donau, Austria** Austria
JOURNAL: International Archives of Allergy and Immunology 126 (1): p78-90 September, 2001 2001
MEDIUM: print
ISSN: 1018-2438
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012890151 BIOSIS NO.: 200100061990
P-selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration
AUTHOR: Hirata Takako; Merrill-Skoloff Glenn; Aab Melissa; Yang Jing; Furie Barbara C; Furie Bruce (Reprint)
AUTHOR ADDRESS: Beth Israel Deaconess Medical Center, Research East No. 319, Boston, MA, 02215, USA**USA
JOURNAL: Journal of Experimental Medicine 192 (11): p1669-1675 December 4, 2000 2000
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011960242 BIOSIS NO.: 199900219902
P- and L-selectin mediate binding of **T cells** to chronically inflamed human airway endothelium
AUTHOR: Symon Fiona A; McNulty Clare A; Wardlaw Andrew J (Reprint)
AUTHOR ADDRESS: Respiratory Medicine, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK**UK
JOURNAL: European Journal of Immunology 29 (4): p1324-1333 April, 1999 1999
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011473259 BIOSIS NO.: 199800267506
Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells. Implications for atherogenesis
AUTHOR: Gerszten Robert E; Lim Yaw-Chyn; Ding Han T; Snapp Karen; Kansas Goeffrey; Dichek David A; Cabanas Carlos; Sanchez-Madrid Francisco; Gimbrone Michael A Jr; Rosenzweig Anthony; Luscinskas Francis W (Reprint)

AUTHOR ADDRESS: Vascular Res. Div., Brigham and Women's Hosp., 221 Longwood Avenue, Boston, MA 02115, USA**USA
JOURNAL: Circulation Research 82 (8): p871-878 May 4, 1998 1998
MEDIUM: print
ISSN: 0009-7330
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011277514 BIOSIS NO.: 199800071761
A novel **P-selectin glycoprotein ligand**-1 monoclonal **antibody** recognizes an epitope within the tyrosine sulfate motif of human **PSGL**-1 and blocks recognition of both P- and L-selectin
AUTHOR: Snapp Karen R; Ding Han; Atkins Kristin; Warnke Roger; Luscinskas Francis W; Kansas Geoffrey S (Reprint)
AUTHOR ADDRESS: Dep. Microbiol.-Immunol., Northwestern Med. Sch., 303 E. Chicago Ave., Chicago, IL 60611, USA**USA
JOURNAL: Blood 91 (1): p154-164 Jan. 1, 1998 1998
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011212160 BIOSIS NO.: 199800006407
The binding of **T cell**-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated
AUTHOR: Borges Eric; Pendl Gunther; Eytner Ruth; Steegmaier Martin; Zoellner Olaf; Vestweber Dietmar (Reprint)
AUTHOR ADDRESS: Inst. Cell Biol., ZMBE, Technol., Mendelstr. 11, D-48149 Muenster, Germany**Germany
JOURNAL: Journal of Biological Chemistry 272 (45): p28786-28792 Nov. 7, 1997 1997
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0010614730 BIOSIS NO.: 199699248790
P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells
AUTHOR: Laszik Zoltan; Jansen Paul J; Cummings Richard D; Tedder Thomas F; McEver Rodger P; Moore Kevin L (Reprint)
AUTHOR ADDRESS: University Oklahoma Health Sci. Cent., 825 NE 13th St., Oklahoma City, OK 73104-5073, USA**USA
JOURNAL: Blood 88 (8): p3010-3021 1996 1996
ISSN: 0006-4971
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

11/3/12 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

12190362 EMBASE No: 2003293119
P-selectin enhances generation of CD14SUP+ CD16SUP+ dendritic-like cells and inhibits macrophage maturation from human peripheral blood monocytes
Li G.; Kim Y.-J.; Mantel C.; Broxmeyer H.E.
Dr. H.E. Broxmeyer, Walther Oncology Center, Indiana Univ. School of Medicine, Building R4, 1044 West Walnut Street, Indianapolis, IN 46202-5254 United States
AUTHOR EMAIL: hbroxmey@iupui.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 JUL 2003, 171/2 (669-677)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 62

11/3/13 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

12182227 EMBASE No: 2003289054
CD8SUP+ **T cells** from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1
Battistini L.; Piccio L.; Rossi B.; Bach S.; Galgani S.; Gasperini C.; Ottoboni L.; Ciabini D.; Caramia M.D.; Bernardi G.; Laudanna C.; Scarpini E.; McEver R.P.; Butcher E.C.; Borsellino G.; Constantin G.
G. Constantin, Department of Pathology, Division of General Pathology, University of Verona, Strada le Grazie 8, Verona 37134 Italy
AUTHOR EMAIL: gabriela.constantin@univr.it
Blood (BLOOD) (United States) 15 JUN 2003, 101/12 (4775-4782)
CODEN: BLOOA ISSN: 0006-4971
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

11/3/14 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

11799410 EMBASE No: 2002370886
P-, E-, and L-selectin mediate migration of activated CD8SUP+ **T lymphocytes** into inflamed skin
Hirata T.; Furie B.C.; Furie B.
Dr. B. Furie, Research East #319, Beth Israel Deaconess Medical Center, P.O. Box 15732, Boston, MA 02215 United States
AUTHOR EMAIL: bfurie@caregroup.harvard.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 OCT 2002, 169/8 (4307-4313)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 44

11/3/15 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

11348541 EMBASE No: 2001361410
IL-12, STAT4-dependent up-regulation of CD4SUP+ **T cell** core 2 beta-1,6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligandsSUP1
Lim Y.; Xie H.; Come C.E.; Alexander S.I.; Grusby M.J.; Lichtman A.H.; Luscinskas F.W.
Dr. F.W. Luscinskas, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115 United States
AUTHOR EMAIL: fluscinskas@rics.bwh.harvard.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 OCT 2001, 167/8 (4476-4484)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 51

11/3/16 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

06773101 EMBASE No: 1997054594
P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin
Borges E.; Tietz W.; Steegmaier M.; Moll T.; Hallmann R.; Hamann A.; Vestweber D.
D. Vestweber, Institute of Cell Biology, ZMBE Technologiehof, Mendelstr. 11, D-48149 Munster Germany
Journal of Experimental Medicine (J. EXP. MED.) (United States) 1997, 185/3 (573-578)
CODEN: JEMEA ISSN: 0022-1007
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 35

11/3/17 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

140092589 CA: 140(7)92589j PATENT
Antibodies or scFv fragments specific to PSGL-1 epitopes useful for diagnosis, prognosis and treatment of cancer, inflammation, infection, autoimmune disease, metastasis and leukemia
INVENTOR(AUTHOR): Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Hoch, Mar-Chaim Hagit
LOCATION: USA
ASSIGNEE: Savient Pharmaceuticals, Inc.
PATENT: PCT International ; WO 200403166 A2 DATE: 20040108
APPLICATION: WO 2003US20602 (20030630) *US 189032 (20020701)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;

BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/18 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

138152275 CA: 138(11)152275z PATENT
Modulators of P-selectin glycoprotein ligand 1
INVENTOR(AUTHOR): Lin, Rong-Hwa; Wu, Chung-Hsiun; Hsu, Pei-Ling
LOCATION: Taiwan,
ASSIGNEE: Abgenomics Co.
PATENT: PCT International ; WO 200313603 A1 DATE: 20030220
APPLICATION: WO 2002US7498 (20020313) *US PV310196 (20010803) *US 51497 (20020118)
PAGES: 44 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07K-016/28B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/19 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

133280563 CA: 133(20)280563a PATENT
Human antibodies that bind human IL-12 and methods for producing
INVENTOR(AUTHOR): Salfeld, Jochen G.; Roguska, Michael; Paskind, Michael; Banerjee, Subhashis; Tracey, Daniel E.; White, Michael; Kaymakcalan, Zehra; Labkovsky, Boris; Sakorafas, Paul; Friedrich, Stuart; Myles, Angela; Veldman, Geertruida M.; Venturini, Amy; Warne, Nicholas W.; Widom, Angela; Elvin, John G.; Duncan, Alexander R.; Derbyshire, Elaine J.; Carmen, Sara; Smith, Stephen; Holtet, Thor Las; Du, Fou Sarah L.
LOCATION: Germany,
ASSIGNEE: Basf A.-G.; Genetics Institute Inc.; et al.
PATENT: PCT International ; WO 200056772 A1 DATE: 20000928
APPLICATION: WO 2000US7946 (20000324) *US PV126603 (19990325)
PAGES: 377 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/24A; C12N-015/13B; C12N-015/63B; C12N-005/10B; C07K-016/00B; A61K-039/395B; G01N-033/577B; C12P-021/08B; A61P-043/00B DESIGNATED COUNTRIES: AE; AG; AL ; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM ; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

11/3/20 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

132303492 CA: 132(23)303492x PATENT
Inhibition of differentiation of T-cells to cytotoxic lymphocytes by P-selectin ligand (PSGL) antagonists
INVENTOR(AUTHOR): Manjunath, Narasimhaswamy; Hans Von Andrian, Ulrich

LOCATION: USA
ASSIGNEE: Genetics Institute, Inc.; CBR Laboratories, Inc.
PATENT: PCT International ; WO 200025808 A1 DATE: 20000511
APPLICATION: WO 99US25501 (19991029) *US PV106315 (19981030)
PAGES: 66 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/16A; A61K-038/17B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
?
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? ds

Set	Items	Description
S1	33	E1-E3
S2	13	E2-E7
S3	0	S(1 OR S2) AND (PSGL?)
S4	15	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND) AND (DIABETES)
S5	10	RD S4 (unique items)
S6	11	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (AUTOIMMUN? OR DIABETES)
S7	10	RD S6 (unique items)
S8	6	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (APOPTOSIS)
S9	5	RD S8 (unique items)
S10	42	(PSGL? OR P(W)SELECTIN(W)GLYCOPROTEIN(W)LIGAND)(10N)(ANTIBOD?) AND (T(W)CELL? OR T(W)LYMPHOCYT? OR NK OR NATURAL(W)KILLER)
S11	20	RD S10 (unique items)
S12	2	S11 AND APOPTOSIS

?